-
1
-
-
84915813644
-
Pancreatic adenocarcinoma
-
Ryan, D.P.; Hong, T.S.; Bardeesy, N. Pancreatic adenocarcinoma. N. Engl. J. Med. 2014, 371, 2140–2141.
-
(2014)
N. Engl. J. Med
, vol.371
, pp. 2140-2141
-
-
Ryan, D.P.1
Hong, T.S.2
Bardeesy, N.3
-
2
-
-
84883670305
-
Recent progress in pancreatic cancer
-
Wolfgang, C.L.; Herman, J.M.; Laheru, D.A.; Klein, A.P.; Erdek, M.A.; Fishman, E.K.; Hruban, R.H. Recent progress in pancreatic cancer. CA Cancer J. Clin. 2013, 63, 318–348.
-
(2013)
CA Cancer J. Clin
, vol.63
, pp. 318-348
-
-
Wolfgang, C.L.1
Herman, J.M.2
Laheru, D.A.3
Klein, A.P.4
Erdek, M.A.5
Fishman, E.K.6
Hruban, R.H.7
-
3
-
-
84923521285
-
Endoscopic and operative palliation strategies for pancreatic ductal adenocarcinoma
-
Stark, A.; Hines, O.J. Endoscopic and operative palliation strategies for pancreatic ductal adenocarcinoma. Semin. Oncol. 2015, 42, 163–176.
-
(2015)
Semin. Oncol
, vol.42
, pp. 163-176
-
-
Stark, A.1
Hines, O.J.2
-
4
-
-
84869091997
-
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
-
Biankin, A.V.; Waddell, N.; Kassahn, K.S.; Gingras, M.C.; Muthuswamy, L.B.; Johns, A.L.; Miller, D.K.; Wilson, P.J.; Patch, A.M.; Wu, J.; et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012, 491, 399–405.
-
(2012)
Nature
, vol.491
, pp. 399-405
-
-
Biankin, A.V.1
Waddell, N.2
Kassahn, K.S.3
Gingras, M.C.4
Muthuswamy, L.B.5
Johns, A.L.6
Miller, D.K.7
Wilson, P.J.8
Patch, A.M.9
Wu, J.10
-
5
-
-
52149123619
-
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
-
Jones, S.; Zhang, X.; Parsons, D.W.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Kamiyama, H.; Jimeno, A.; et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321, 1801–1806.
-
(2008)
Science
, vol.321
, pp. 1801-1806
-
-
Jones, S.1
Zhang, X.2
Parsons, D.W.3
Lin, J.C.4
Leary, R.J.5
Angenendt, P.6
Mankoo, P.7
Carter, H.8
Kamiyama, H.9
Jimeno, A.10
-
6
-
-
84924056345
-
Whole genomes redefine the mutational landscape of pancreatic cancer
-
Waddell, N.; Pajic, M.; Patch, A.M.; Chang, D.K.; Kassahn, K.S.; Bailey, P.; Johns, A.L.; Miller, D.; Nones, K.; Quek, K.; et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015, 518, 495–501.
-
(2015)
Nature
, vol.518
, pp. 495-501
-
-
Waddell, N.1
Pajic, M.2
Patch, A.M.3
Chang, D.K.4
Kassahn, K.S.5
Bailey, P.6
Johns, A.L.7
Miller, D.8
Nones, K.9
Quek, K.10
-
7
-
-
84927144113
-
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
-
Witkiewicz, A.K.; McMillan, E.A.; Balaji, U.; Baek, G.; Lin, W.C.; Mansour, J.; Mollaee, M.; Wagner, K.U.; Koduru, P.; Yopp, A.; et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 2015.
-
(2015)
Nat. Commun
-
-
Witkiewicz, A.K.1
McMillan, E.A.2
Balaji, U.3
Baek, G.4
Lin, W.C.5
Mansour, J.6
Mollaee, M.7
Wagner, K.U.8
Koduru, P.9
Yopp, A.10
-
8
-
-
84860321700
-
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
-
Ying, H.; Kimmelman, A.C.; Lyssiotis, C.A.; Hua, S.; Chu, G.C.; Fletcher-Sananikone, E.; Locasale, J.W.; Son, J.; Zhang, H.; Coloff, J.L.; et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012, 149, 656–670.
-
(2012)
Cell
, vol.149
, pp. 656-670
-
-
Ying, H.1
Kimmelman, A.C.2
Lyssiotis, C.A.3
Hua, S.4
Chu, G.C.5
Fletcher-Sananikone, E.6
Locasale, J.W.7
Son, J.8
Zhang, H.9
Coloff, J.L.10
-
9
-
-
84863012865
-
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
-
Collins, M.A.; Bednar, F.; Zhang, Y.; Brisset, J.C.; Galbán, S.; Galbán, C.J.; Rakshit, S.; Flannagan, K.S.; Adsay, N.V.; Pasca di Magliano, M. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clin. Investig. 2012, 122, 639–653.
-
(2012)
J. Clin. Investig
, vol.122
, pp. 639-653
-
-
Collins, M.A.1
Bednar, F.2
Zhang, Y.3
Brisset, J.C.4
Galbán, S.5
Galbán, C.J.6
Rakshit, S.7
Flannagan, K.S.8
Adsay, N.V.9
Pasca Di Magliano, M.10
-
10
-
-
0036726313
-
Stable suppression of tumorigenicity by virus-mediated RNA interference
-
Brummelkamp, T.R.; Bernards, R.; Agami, R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002, 2, 243–247.
-
(2002)
Cancer Cell
, vol.2
, pp. 243-247
-
-
Brummelkamp, T.R.1
Bernards, R.2
Agami, R.3
-
12
-
-
84896090174
-
Dragging RAS back in the ring
-
Stephen, A.G.; Esposito, D.; Bagni, R.K.; McCormick, F. Dragging RAS back in the ring. Cancer Cell 2014, 25, 272–281.
-
(2014)
Cancer Cell
, vol.25
, pp. 272-281
-
-
Stephen, A.G.1
Esposito, D.2
Bagni, R.K.3
McCormick, F.4
-
13
-
-
84892861646
-
KRAS: Feeding pancreatic cancer proliferation
-
Bryant, K.L.; Mancias, J.D.; Kimmelman, A.C.; Der, C.J. KRAS: Feeding pancreatic cancer proliferation. Trends Biochem. Sci. 2014, 39, 91–100.
-
(2014)
Trends Biochem. Sci
, vol.39
, pp. 91-100
-
-
Bryant, K.L.1
Mancias, J.D.2
Kimmelman, A.C.3
Der, C.J.4
-
14
-
-
84908491115
-
Drugging the undruggable RAS: Mission possible?
-
Cox, A.D.; Fesik, S.W.; Kimmelman, A.C.; Luo, J.; Der, C.J. Drugging the undruggable RAS: Mission possible? Nat. Rev. Drug Discov. 2014, 13, 828–851.
-
(2014)
Nat. Rev. Drug Discov
, vol.13
, pp. 828-851
-
-
Cox, A.D.1
Fesik, S.W.2
Kimmelman, A.C.3
Luo, J.4
Der, C.J.5
-
15
-
-
84922287331
-
K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif
-
Tsai, F.D.; Lopes, M.S.; Zhou, M.; Court, H.; Ponce, O.; Fiordalisi, J.J.; Gierut, J.J.; Cox, A.D.; Haigis, K.M.; Philips, M.R. K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif. Proc. Natl. Acad. Sci. USA 2015, 112, 779–784.
-
(2015)
Proc. Natl. Acad. Sci. USA
, vol.112
, pp. 779-784
-
-
Tsai, F.D.1
Lopes, M.S.2
Zhou, M.3
Court, H.4
Ponce, O.5
Fiordalisi, J.J.6
Gierut, J.J.7
Cox, A.D.8
Haigis, K.M.9
Philips, M.R.10
-
16
-
-
84927620483
-
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
-
Cox, A.D.; Der, C.J.; Philips, M.R. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery? Clin. Cancer Res. 2015, 21, 1819–1827.
-
(2015)
Clin. Cancer Res
, vol.21
, pp. 1819-1827
-
-
Cox, A.D.1
Der, C.J.2
Philips, M.R.3
-
17
-
-
78649487698
-
RAS superfamily GEFs and GAPs: Validated and tractable targets for cancer therapy?
-
Vigil, D.; Cherfils, J.; Rossman, K.L.; Der, C.J. RAS superfamily GEFs and GAPs: Validated and tractable targets for cancer therapy? Nat. Rev. Cancer 2010, 10, 842–857.
-
(2010)
Nat. Rev. Cancer
, vol.10
, pp. 842-857
-
-
Vigil, D.1
Cherfils, J.2
Rossman, K.L.3
Der, C.J.4
-
18
-
-
84861147473
-
A comprehensive survey of RAS mutations in cancer
-
Prior, I.A.; Lewis, P.D.; Mattos, C. A comprehensive survey of RAS mutations in cancer. Cancer Res. 2012, 72, 2457–2467.
-
(2012)
Cancer Res
, vol.72
, pp. 2457-2467
-
-
Prior, I.A.1
Lewis, P.D.2
Mattos, C.3
-
19
-
-
78649474147
-
Ras history: The saga continues
-
Cox, A.D.; Der, C.J. Ras history: The saga continues. Small GTPases 2010, 1, 2–27.
-
(2010)
Small Gtpases
, vol.1
, pp. 2-27
-
-
Cox, A.D.1
Der, C.J.2
-
20
-
-
0030772378
-
The Ras-RasGAP complex: Structural basis for GTPase activation and its loss in oncogenic RAS mutants
-
Scheffzek, K.; Ahmadian, M.R.; Kabsch, W.; Wiesmüller, L.; Lautwein, A.; Schmitz, F.; Wittinghofer, A. The Ras-RasGAP complex: Structural basis for GTPase activation and its loss in oncogenic RAS mutants. Science 1997, 277, 333–338.
-
(1997)
Science
, vol.277
, pp. 333-338
-
-
Scheffzek, K.1
Ahmadian, M.R.2
Kabsch, W.3
Wiesmüller, L.4
Lautwein, A.5
Schmitz, F.6
Wittinghofer, A.7
-
21
-
-
0033571343
-
The pre-hydrolysis state of p21 (RAS) in complex with GTP: New insights into the role of water molecules in the GTP hydrolysis reaction of ras-like proteins
-
Scheidig, A.J.; Burmester, C.; Goody, R.S. The pre-hydrolysis state of p21 (RAS) in complex with GTP: New insights into the role of water molecules in the GTP hydrolysis reaction of ras-like proteins. Structure 1999, 7, 1311–1324.
-
(1999)
Structure
, vol.7
, pp. 1311-1324
-
-
Scheidig, A.J.1
Burmester, C.2
Goody, R.S.3
-
22
-
-
84862777152
-
Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia
-
Kanda, M.; Matthaei, H.; Wu, J.; Hong, S.M.; Yu, J.; Borges, M.; Hruban, R.H.; Maitra, A.; Kinzler, K.; Vogelstein, B.; Goggins, M. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 2012, 142, 730–733.
-
(2012)
Gastroenterology
, vol.142
, pp. 730-733
-
-
Kanda, M.1
Matthaei, H.2
Wu, J.3
Hong, S.M.4
Yu, J.5
Borges, M.6
Hruban, R.H.7
Maitra, A.8
Kinzler, K.9
Vogelstein, B.10
Goggins, M.11
-
23
-
-
84865068802
-
Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer
-
Hong, S.M.; Vincent, A.; Kanda, M.; Leclerc, J.; Omura, N.; Borges, M.; Klein, A.P.; Canto, M.I.; Hruban, R.H.; Goggins, M. Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer. Clin. Cancer Res. 2012, 18, 4303–4312.
-
(2012)
Clin. Cancer Res
, vol.18
, pp. 4303-4312
-
-
Hong, S.M.1
Vincent, A.2
Kanda, M.3
Leclerc, J.4
Omura, N.5
Borges, M.6
Klein, A.P.7
Canto, M.I.8
Hruban, R.H.9
Goggins, M.10
-
24
-
-
80051700067
-
Pancreatic cancer
-
Vincent, A.; Herman, J.; Schulick, R.; Hruban, R.H.; Goggins, M. Pancreatic cancer. Lancet 2011, 378, 607–620.
-
(2011)
Lancet
, vol.378
, pp. 607-620
-
-
Vincent, A.1
Herman, J.2
Schulick, R.3
Hruban, R.H.4
Goggins, M.5
-
25
-
-
16944367477
-
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas
-
Schutte, M.; Hruban, R.H.; Geradts, J.; Maynard, R.; Hilgers, W.; Rabindran, S.K.; Moskaluk, C.A.; Hahn, S.A.; Schwarte-Waldhoff, I.; Schmiegel, W.; et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997, 57, 3126–3130.
-
(1997)
Cancer Res
, vol.57
, pp. 3126-3130
-
-
Schutte, M.1
Hruban, R.H.2
Geradts, J.3
Maynard, R.4
Hilgers, W.5
Rabindran, S.K.6
Moskaluk, C.A.7
Hahn, S.A.8
Schwarte-Waldhoff, I.9
Schmiegel, W.10
-
26
-
-
84862757239
-
Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer
-
Malkoski, S.P.; Wang, X.J. Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer. FEBS Lett. 2012, 586, 1984–1992.
-
(2012)
FEBS Lett
, vol.586
, pp. 1984-1992
-
-
Malkoski, S.P.1
Wang, X.J.2
-
27
-
-
84862649997
-
Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation
-
Sun, Q.; Burke, J.P.; Phan, J.; Burns, M.C.; Olejniczak, E.T.; Waterson, A.G.; Lee, T.; Rossanese, O.W.; Fesik, S.W. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew. Chem. Int. Ed. Engl. 2012, 51, 6140–6143.
-
Angew. Chem. Int. Ed. Engl
, pp. 6140-6143
-
-
Sun, Q.1
Burke, J.P.2
Phan, J.3
Burns, M.C.4
Olejniczak, E.T.5
Waterson, A.G.6
Lee, T.7
Rossanese, O.W.8
Fesik, S.W.9
-
28
-
-
84859463451
-
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity
-
Maurer, T.; Garrenton, L.S.; Oh, A.; Pitts, K.; Anderson, D.J.; Skelton, N.J.; Fauber, B.P.; Pan, B.; Malek, S.; Stokoe, D.; et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl. Acad. Sci. USA 2012, 109, 5299–5304.
-
(2012)
Proc. Natl. Acad. Sci. USA
, vol.109
, pp. 5299-5304
-
-
Maurer, T.1
Garrenton, L.S.2
Oh, A.3
Pitts, K.4
Anderson, D.J.5
Skelton, N.J.6
Fauber, B.P.7
Pan, B.8
Malek, S.9
Stokoe, D.10
-
29
-
-
84895834287
-
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
-
Burns, M.C.; Sun, Q.; Daniels, R.N.; Camper, D.; Kennedy, J.P.; Phan, J.; Olejniczak, E.T.; Lee, T.; Waterson, A.G.; Rossanese, O.W.; et al. Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. Proc. Natl. Acad. Sci. USA 2014, 111, 3401–3406.
-
(2014)
Proc. Natl. Acad. Sci. USA
, vol.111
, pp. 3401-3406
-
-
Burns, M.C.1
Sun, Q.2
Daniels, R.N.3
Camper, D.4
Kennedy, J.P.5
Phan, J.6
Olejniczak, E.T.7
Lee, T.8
Waterson, A.G.9
Rossanese, O.W.10
-
30
-
-
84877863454
-
In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction
-
Shima, F.; Yoshikawa, Y.; Ye, M.; Araki, M.; Matsumoto, S.; Liao, J.; Hu, L.; Sugimoto, T.; Ijiri, Y.; Takeda, A.; et al. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc. Natl. Acad. Sci. USA 2013, 110, 8182–8187.
-
(2013)
Proc. Natl. Acad. Sci. USA
, vol.110
, pp. 8182-8187
-
-
Shima, F.1
Yoshikawa, Y.2
Ye, M.3
Araki, M.4
Matsumoto, S.5
Liao, J.6
Hu, L.7
Sugimoto, T.8
Ijiri, Y.9
Takeda, A.10
-
31
-
-
84888639050
-
K-RAS (G12C) inhibitors allosterically control GTP affinity and effector interactions
-
Ostrem, J.M.; Peters, U.; Sos, M.L.; Wells, J.A.; Shokat, K.M. K-RAS (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503, 548–551.
-
(2013)
Nature
, vol.503
, pp. 548-551
-
-
Ostrem, J.M.1
Peters, U.2
Sos, M.L.3
Wells, J.A.4
Shokat, K.M.5
-
32
-
-
84890947640
-
Therapeutic targeting of oncogenic K-RAS by a covalent catalytic site inhibitor
-
Lim, S.M.; Westover, K.D.; Ficarro, S.B.; Harrison, R.A.; Choi, H.G.; Pacold, M.E.; Carrasco, M.; Hunter, J.; Kim, N.D.; Xie, T.; et al. Therapeutic targeting of oncogenic K-RAS by a covalent catalytic site inhibitor. Angew. Chem. Int. Ed. Engl. 2014, 53, 199–204.
-
(2014)
Angew. Chem. Int. Ed. Engl
, vol.53
, pp. 199-204
-
-
Lim, S.M.1
Westover, K.D.2
Ficarro, S.B.3
Harrison, R.A.4
Choi, H.G.5
Pacold, M.E.6
Carrasco, M.7
Hunter, J.8
Kim, N.D.9
Xie, T.10
-
33
-
-
84907528772
-
Development of siRNA payloads to target KRAS-mutant cancer
-
Yuan, T.L.; Fellmann, C.; Lee, C.S.; Ritchie, C.D.; Thapar, V.; Lee, L.C.; Hsu, D.J.; Grace, D.; Carver, J.O.; Zuber, J.; et al. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov. 2014, 4, 1182–1197.
-
(2014)
Cancer Discov
, vol.4
, pp. 1182-1197
-
-
Yuan, T.L.1
Fellmann, C.2
Lee, C.S.3
Ritchie, C.D.4
Thapar, V.5
Lee, L.C.6
Hsu, D.J.7
Grace, D.8
Carver, J.O.9
Zuber, J.10
-
34
-
-
84906706945
-
Small RNA combination therapy for lung cancer
-
Xue, W.; Dahlman, J.E.; Tammela, T.; Khan, O.F.; Sood, S.; Dave, A.; Cai, W.; Chirino, L.M.; Yang, G.R.; Bronson, R.; et al. Small RNA combination therapy for lung cancer. Proc. Natl. Acad. Sci. USA 2014, 111, 3553–3661.
-
(2014)
Proc. Natl. Acad. Sci. USA
, vol.111
, pp. 3553-3661
-
-
Xue, W.1
Dahlman, J.E.2
Tammela, T.3
Khan, O.F.4
Sood, S.5
Dave, A.6
Cai, W.7
Chirino, L.M.8
Yang, G.R.9
Bronson, R.10
-
35
-
-
27644556527
-
Reduction in the requirement of oncogenic RAS signaling to activation of PI3K/AKT pathway during tumor maintenance
-
Lim, K.H.; Counter, C.M. Reduction in the requirement of oncogenic RAS signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell 2005, 8, 381–392.
-
(2005)
Cancer Cell
, vol.8
, pp. 381-392
-
-
Lim, K.H.1
Counter, C.M.2
-
36
-
-
22944447177
-
Molecular consequences of silencing mutant K-RAS in pancreatic cancer cells: Justification for K-RAS-directed therapy
-
Fleming, J.B.; Shen, G.L.; Holloway, S.E.; Davis, M.; Brekken, R.A. Molecular consequences of silencing mutant K-RAS in pancreatic cancer cells: Justification for K-RAS-directed therapy. Mol. Cancer Res. 2005, 3, 413–423.
-
(2005)
Mol. Cancer Res.
, vol.3
, pp. 413-423
-
-
Fleming, J.B.1
Shen, G.L.2
Holloway, S.E.3
Davis, M.4
Brekken, R.A.5
-
37
-
-
84890824325
-
Mutant KRAS is a druggable target for pancreatic cancer
-
Zorde Khvalevsky, E.; Gabai, R.; Rachmut, I.H.; Horwitz, E.; Brunschwig, Z.; Orbach, A.; Shemi, A.; Golan, T.; Domb, A.J.; Yavin, E.; et al. Mutant KRAS is a druggable target for pancreatic cancer. Proc. Natl. Acad. Sci. USA 2013, 110, 20723–20728.
-
(2013)
Proc. Natl. Acad. Sci. USA
, vol.110
, pp. 20723-20728
-
-
Zorde Khvalevsky, E.1
Gabai, R.2
Rachmut, I.H.3
Horwitz, E.4
Brunschwig, Z.5
Orbach, A.6
Shemi, A.7
Golan, T.8
Domb, A.J.9
Yavin, E.10
-
38
-
-
84941262148
-
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
-
Golan, T.; Khvalevsky, E.Z.; Hubert, A.; Gabai, R.M.; Hen, N.; Segal, A.; Domb, A.; Harari, G.; David, E.B.; Raskin, S.; et al. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget 2015, 6, 24560–24570.
-
(2015)
Oncotarget
, vol.6
, pp. 24560-24570
-
-
Golan, T.1
Khvalevsky, E.Z.2
Hubert, A.3
Gabai, R.M.4
Hen, N.5
Segal, A.6
Domb, A.7
Harari, G.8
David, E.B.9
Raskin, S.10
-
39
-
-
84918495709
-
Therapeutic silencing of KRAS using systemically delivered siRNAs
-
Pecot, C.V.; Wu, S.Y.; Bellister, S.; Filant, J.; Rupaimoole, R.; Hisamatsu, T.; Bhattacharya, R.; Maharaj, A.; Azam, S.; Rodriguez-Aguayo, C.; et al. Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol. Cancer Ther. 2014, 13, 2876–2885.
-
(2014)
Mol. Cancer Ther
, vol.13
, pp. 2876-2885
-
-
Pecot, C.V.1
Wu, S.Y.2
Bellister, S.3
Filant, J.4
Rupaimoole, R.5
Hisamatsu, T.6
Bhattacharya, R.7
Maharaj, A.8
Azam, S.9
Rodriguez-Aguayo, C.10
-
40
-
-
84255195028
-
Regulating the regulator: Post-translational modification of RAS
-
Ahearn, I.M.; Haigis, K.; Bar-Sagi, D.; Philips, M.R. Regulating the regulator: Post-translational modification of RAS. Nat. Rev. Mol. Cell Biol. 2012, 13, 39–51.
-
(2012)
Nat. Rev. Mol. Cell Biol
, vol.13
, pp. 39-51
-
-
Ahearn, I.M.1
Haigis, K.2
Bar-Sagi, D.3
Philips, M.R.4
-
41
-
-
30844467746
-
Lipid posttranslational modifications. Farnesyl transferase inhibitors
-
Basso, A.D.; Kirschmeier, P.; Bishop, W.R. Lipid posttranslational modifications. Farnesyl transferase inhibitors. J. Lipid Res. 2006, 47, 15–31.
-
(2006)
J. Lipid Res
, vol.47
, pp. 15-31
-
-
Basso, A.D.1
Kirschmeier, P.2
Bishop, W.R.3
-
42
-
-
80054866000
-
Targeting protein prenylation for cancer therapy
-
Berndt, N.; Hamilton, A.D.; Sebti, S.M. Targeting protein prenylation for cancer therapy. Nat. Rev. Cancer 2011, 11, 775–791.
-
(2011)
Nat. Rev. Cancer
, vol.11
, pp. 775-791
-
-
Berndt, N.1
Hamilton, A.D.2
Sebti, S.M.3
-
43
-
-
23844517889
-
A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study
-
Macdonald, J.S.; McCoy, S.; Whitehead, R.P.; Iqbal, S.; Wade, J.L.; Giguere, J.K.; Abbruzzese, J.L. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study. Investig. New Drugs 2005, 23, 485–487.
-
(2005)
Investig. New Drugs
, vol.23
, pp. 485-487
-
-
Macdonald, J.S.1
McCoy, S.2
Whitehead, R.P.3
Iqbal, S.4
Wade, J.L.5
Giguere, J.K.6
Abbruzzese, J.L.7
-
44
-
-
0038413837
-
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma
-
Cohen, S.J.; Ho, L.; Ranganathan, S.; Abbruzzese, J.L.; Alpaugh, R.K.; Beard, M.; Lewis, N.L.; McLaughlin, S.; Rogatko, A.; Perez-Ruixo, J.J.; et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 2003, 21, 1301–1306.
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 1301-1306
-
-
Cohen, S.J.1
Ho, L.2
Ranganathan, S.3
Abbruzzese, J.L.4
Alpaugh, R.K.5
Beard, M.6
Lewis, N.L.7
McLaughlin, S.8
Rogatko, A.9
Perez-Ruixo, J.J.10
-
45
-
-
2342645506
-
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
-
Van Cutsem, E.; van de Velde, H.; Karasek, P.; Oettle, H.; Vervenne, W.L.; Szawlowski, A.; Schoffski, P.; Post, S.; Verslype, C.; Neumann, H.; et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 2004, 22, 1430–1438.
-
(2004)
J. Clin. Oncol.
, vol.22
, pp. 1430-1438
-
-
Van Cutsem, E.1
Van De Velde, H.2
Karasek, P.3
Oettle, H.4
Vervenne, W.L.5
Szawlowski, A.6
Schoffski, P.7
Post, S.8
Verslype, C.9
Neumann, H.10
-
46
-
-
38949093546
-
Inhibitors of chronically active ras: Potential for treatment of human malignancies
-
Blum, R.; Cox, A.D.; Kloog, Y. Inhibitors of chronically active ras: Potential for treatment of human malignancies. Recent Pat. Anticancer Drug Discov. 2008, 3, 31–47.
-
(2008)
Recent Pat. Anticancer Drug Discov
, vol.3
, pp. 31-47
-
-
Blum, R.1
Cox, A.D.2
Kloog, Y.3
-
47
-
-
0032477606
-
Dislodgment and accelerated degradation of Ras
-
Haklai, R.; Weisz, M.G.; Elad, G.; Paz, A.; Marciano, D.; Egozi, Y.; Ben-Baruch, G.; Kloog, Y. Dislodgment and accelerated degradation of Ras. Biochemistry 1998, 37, 1306–1314.
-
(1998)
Biochemistry
, vol.37
, pp. 1306-1314
-
-
Haklai, R.1
Weisz, M.G.2
Elad, G.3
Paz, A.4
Marciano, D.5
Egozi, Y.6
Ben-Baruch, G.7
Kloog, Y.8
-
48
-
-
0028981375
-
Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid
-
Marom, M.; Haklai, R.; Ben-Baruch, G.; Marciano, D.; Egozi, Y.; Kloog, Y. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J. Biol. Chem. 1995, 270, 22263–22270.
-
(1995)
J. Biol. Chem
, vol.270
, pp. 22263-22270
-
-
Marom, M.1
Haklai, R.2
Ben-Baruch, G.3
Marciano, D.4
Egozi, Y.5
Kloog, Y.6
-
49
-
-
80051745051
-
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations
-
Riely, G.J.; Johnson, M.L.; Medina, C.; Rizvi, N.A.; Miller, V.A.; Kris, M.G.; Pietanza, M.C.; Azzoli, C.G.; Krug, L.M.; Pao, W.; et al. A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. J. Thorac. Oncol. 2011, 6, 1435–1437.
-
(2011)
J. Thorac. Oncol.
, vol.6
, pp. 1435-1437
-
-
Riely, G.J.1
Johnson, M.L.2
Medina, C.3
Rizvi, N.A.4
Miller, V.A.5
Kris, M.G.6
Pietanza, M.C.7
Azzoli, C.G.8
Krug, L.M.9
Pao, W.10
-
50
-
-
84856492497
-
The GDI-like solubilizing factor PDE sustains the spatial organization and signaling of Ras family proteins
-
Chandra, A.; Grecco, H.E.; Pisupati, V.; Perera, D.; Cassidy, L.; Skoulidis, F.; Ismail, S.A.; Hedberg, C.; Hanzal-Bayer, M.; Venkitaraman, A.R.; et al. The GDI-like solubilizing factor PDE sustains the spatial organization and signaling of Ras family proteins. Nat. Cell Biol. 2012, 14, 148–158.
-
(2012)
Nat. Cell Biol
, vol.14
, pp. 148-158
-
-
Chandra, A.1
Grecco, H.E.2
Pisupati, V.3
Perera, D.4
Cassidy, L.5
Skoulidis, F.6
Ismail, S.A.7
Hedberg, C.8
Hanzal-Bayer, M.9
Venkitaraman, A.R.10
-
51
-
-
84878401236
-
Small molecule inhibition of the KRAS-PDE interaction impairs oncogenic KRAS signalling
-
Zimmermann, G.; Papke, B.; Ismail, S.; Vartak, N.; Chandra, A.; Hoffmann, M.; Hahn, S.A.; Triola, G.; Wittinghofer, A.; Bastiaens, P.I.; et al. Small molecule inhibition of the KRAS-PDE interaction impairs oncogenic KRAS signalling. Nature 2013, 497, 638–642.
-
(2013)
Nature
, vol.497
, pp. 638-642
-
-
Zimmermann, G.1
Papke, B.2
Ismail, S.3
Vartak, N.4
Chandra, A.5
Hoffmann, M.6
Hahn, S.A.7
Triola, G.8
Wittinghofer, A.9
Bastiaens, P.I.10
-
52
-
-
67949088074
-
Ras/MAPK signaling from endomembranes
-
Fehrenbacher, N.; Bar-Sagi, D.; Philips, M. Ras/MAPK signaling from endomembranes. Mol. Oncol. 2009, 3, 297–307.
-
(2009)
Mol. Oncol
, vol.3
, pp. 297-307
-
-
Fehrenbacher, N.1
Bar-Sagi, D.2
Philips, M.3
-
53
-
-
32444441115
-
PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis
-
Bivona, T.G.; Quatela, S.E.; Bodemann, B.O.; Ahearn, I.M.; Soskis, M.J.; Mor, A.; Miura, J.; Wiener, H.H.; Wright, L.; Saba, S.G.; et al. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol. Cell 2006, 21, 481–493.
-
(2006)
Mol. Cell
, vol.21
, pp. 481-493
-
-
Bivona, T.G.1
Quatela, S.E.2
Bodemann, B.O.3
Ahearn, I.M.4
Soskis, M.J.5
Mor, A.6
Miura, J.7
Wiener, H.H.8
Wright, L.9
Saba, S.G.10
-
54
-
-
84890835716
-
Phosphorylated K-Ras limits cell survival by blocking Bcl-xL sensitization of inositol trisphosphate receptors
-
Sung, P.J.; Tsai, F.D.; Vais, H.; Court, H.; Yang, J.; Fehrenbacher, N.; Foskett, J.K.; Philips, M.R. Phosphorylated K-Ras limits cell survival by blocking Bcl-xL sensitization of inositol trisphosphate receptors. Proc. Natl. Acad. Sci. USA 2013, 110, 20593–20598.
-
(2013)
Proc. Natl. Acad. Sci. USA
, vol.110
, pp. 20593-20598
-
-
Sung, P.J.1
Tsai, F.D.2
Vais, H.3
Court, H.4
Yang, J.5
Fehrenbacher, N.6
Foskett, J.K.7
Philips, M.R.8
-
55
-
-
84894236975
-
Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth
-
Barceló, C.; Paco, N.; Morell, M.; Alvarez-Moya, B.; Bota-Rabassedas, N.; Jaumot, M.; Vilardell, F.; Capella, G.; Agell, N. Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth. Cancer Res. 2014, 74, 1190–1199.
-
(2014)
Cancer Res
, vol.74
, pp. 1190-1199
-
-
Barceló, C.1
Paco, N.2
Morell, M.3
Alvarez-Moya, B.4
Bota-Rabassedas, N.5
Jaumot, M.6
Vilardell, F.7
Capella, G.8
Agell, N.9
-
56
-
-
0031962146
-
Establishment of a human pancreatic tumor xenograft model: Potential application for preclinical evaluation of novel therapeutic agents
-
Mohammad, R.M.; Dugan, M.C.; Mohamed, A.N.; Almatchy, V.P.; Flake, T.M.; Dergham, S.T.; Shields, A.F.; Al-Katib, A.A.; Vaitkevicius, V.K.; Sarkar, F.H. Establishment of a human pancreatic tumor xenograft model: Potential application for preclinical evaluation of novel therapeutic agents. Pancreas 1998, 16, 19–25.
-
(1998)
Pancreas
, vol.16
, pp. 19-25
-
-
Mohammad, R.M.1
Dugan, M.C.2
Mohamed, A.N.3
Almatchy, V.P.4
Flake, T.M.5
Dergham, S.T.6
Shields, A.F.7
Al-Katib, A.A.8
Vaitkevicius, V.K.9
Sarkar, F.H.10
-
57
-
-
0033126464
-
Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine
-
Mohammad, R.M.; Limvarapuss, C.; Hamdy, N.; Dutcher, B.S.; Beck, F.W.; Wall, N.R.; Al-Katib, A.M. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine. Int. J. Oncol. 1999, 14, 945–950.
-
(1999)
Int. J. Oncol
, vol.14
, pp. 945-950
-
-
Mohammad, R.M.1
Limvarapuss, C.2
Hamdy, N.3
Dutcher, B.S.4
Beck, F.W.5
Wall, N.R.6
Al-Katib, A.M.7
-
58
-
-
84891799728
-
Marine natural products: Bryostatins in preclinical and clinical studies
-
Kollár, P.; Rajchard, J.; Balounová, Z.; Pazourek, J. Marine natural products: Bryostatins in preclinical and clinical studies. Pharm. Biol. 2014, 52, 237–242.
-
(2014)
Pharm. Biol
, vol.52
, pp. 237-242
-
-
Kollár, P.1
Rajchard, J.2
Balounová, Z.3
Pazourek, J.4
-
59
-
-
0039923005
-
Marine organisms as a source of new anticancer agents
-
Schwartsmann, G.; Brondani da Rocha, A.; Berlinck, R.G.; Jimeno, J. Marine organisms as a source of new anticancer agents. Lancet Oncol. 2001, 2, 221–225.
-
(2001)
Lancet Oncol
, vol.2
, pp. 221-225
-
-
Schwartsmann, G.1
Brondani Da Rocha, A.2
Berlinck, R.G.3
Jimeno, J.4
-
60
-
-
79952284127
-
Hallmarks of cancer: The next generation
-
Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674.
-
(2011)
Cell
, vol.144
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
61
-
-
61449182121
-
Principles of cancer therapy: Oncogene and non-oncogene addiction
-
Luo, J.; Solimini, N.L.; Elledge, S.J. Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell 2009, 136, 823–837.
-
(2009)
Cell
, vol.136
, pp. 823-837
-
-
Luo, J.1
Solimini, N.L.2
Elledge, S.J.3
-
62
-
-
84964229409
-
Inhibitors of the Ras superfamily of small G-proteins
-
Tamanoi, F.; Der, C.J. Inhibitors of the Ras superfamily of small G-proteins. Preface. Enzymes 2013.
-
(2013)
Preface. Enzymes
-
-
Tamanoi, F.1
Der, C.J.2
-
63
-
-
33846846261
-
Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells
-
Sarthy, A.V.; Morgan-Lappe, S.E.; Zakula, D.; Vernetti, L.; Schurdak, M.; Packer, J.C.; Anderson, M.G.; Shirasawa, S.; Sasazuki, T.; Fesik, S.W. Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Mol. Cancer Ther. 2007, 6, 269–276.
-
(2007)
Mol. Cancer Ther
, vol.6
, pp. 269-276
-
-
Sarthy, A.V.1
Morgan-Lappe, S.E.2
Zakula, D.3
Vernetti, L.4
Schurdak, M.5
Packer, J.C.6
Anderson, M.G.7
Shirasawa, S.8
Sasazuki, T.9
Fesik, S.W.10
-
64
-
-
34249285532
-
Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen
-
Morgan-Lappe, S.E.; Tucker, L.A.; Huang, X.; Zhang, Q.; Sarthy, A.V.; Zakula, D.; Vernetti, L.; Schurdak, M.; Wang, J.; Fesik, S.W. Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Res. 2007, 67, 4390–4398.
-
(2007)
Cancer Res
, vol.67
, pp. 4390-4398
-
-
Morgan-Lappe, S.E.1
Tucker, L.A.2
Huang, X.3
Zhang, Q.4
Sarthy, A.V.5
Zakula, D.6
Vernetti, L.7
Schurdak, M.8
Wang, J.9
Fesik, S.W.10
-
65
-
-
84865015653
-
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies
-
Steckel, M.; Molina-Arcas, M.; Weigelt, B.; Marani, M.; Warne, P.H.; Kuznetsov, H.; Kelly, G.; Saunders, B.; Howell, M.; Downward, J.; et al. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res. 2012, 22, 1227–1245.
-
(2012)
Cell Res.
, vol.22
, pp. 1227-1245
-
-
Steckel, M.1
Molina-Arcas, M.2
Weigelt, B.3
Marani, M.4
Warne, P.H.5
Kuznetsov, H.6
Kelly, G.7
Saunders, B.8
Howell, M.9
Downward, J.10
-
66
-
-
84860319361
-
The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer
-
Kumar, M.S.; Hancock, D.C.; Molina-Arcas, M.; Steckel, M.; East, P.; Diefenbacher, M.; Armenteros-Monterroso, E.; Lassailly, F.; Matthews, N.; Nye, E.; et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 2012, 149, 642–655.
-
(2012)
Cell
, vol.149
, pp. 642-655
-
-
Kumar, M.S.1
Hancock, D.C.2
Molina-Arcas, M.3
Steckel, M.4
East, P.5
Diefenbacher, M.6
Armenteros-Monterroso, E.7
Lassailly, F.8
Matthews, N.9
Nye, E.10
-
67
-
-
65849111219
-
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells
-
Scholl, C.; Fröhling, S.; Dunn, I.F.; Schinzel, A.C.; Barbie, D.A.; Kim, S.Y.; Silver, S.J.; Tamayo, P.; Wadlow, R.C.; Ramaswamy, S.; et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009, 137, 821–834.
-
(2009)
Cell
, vol.137
, pp. 821-834
-
-
Scholl, C.1
Fröhling, S.2
Dunn, I.F.3
Schinzel, A.C.4
Barbie, D.A.5
Kim, S.Y.6
Silver, S.J.7
Tamayo, P.8
Wadlow, R.C.9
Ramaswamy, S.10
-
68
-
-
84857422433
-
STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability
-
Luo, T.; Masson, K.; Jaffe, J.D.; Silkworth, W.; Ross, N.T.; Scherer, C.A.; Scholl, C.; Fröhling, S.; Carr, S.A.; Stern, A.M.; et al. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc. Natl. Acad. Sci. USA 2012, 109, 2860–2865.
-
(2012)
Proc. Natl. Acad. Sci. USA
, vol.109
, pp. 2860-2865
-
-
Luo, T.1
Masson, K.2
Jaffe, J.D.3
Silkworth, W.4
Ross, N.T.5
Scherer, C.A.6
Scholl, C.7
Fröhling, S.8
Carr, S.A.9
Stern, A.M.10
-
69
-
-
70449091786
-
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
-
Barbie, D.A.; Tamayo, P.; Boehm, J.S.; Kim, S.Y.; Moody, S.E.; Dunn, I.F.; Schinzel, A.C.; Sandy, P.; Meylan, E.; Scholl, C.; et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462, 108–112.
-
(2009)
Nature
, vol.462
, pp. 108-112
-
-
Barbie, D.A.1
Tamayo, P.2
Boehm, J.S.3
Kim, S.Y.4
Moody, S.E.5
Dunn, I.F.6
Schinzel, A.C.7
Sandy, P.8
Meylan, E.9
Scholl, C.10
-
70
-
-
84904258149
-
Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. Mol
-
Muvaffak, A.; Pan, Q.; Yan, H.; Fernandez, R.; Lim, J.; Dolinski, B.; Nguyen, T.T.; Strack, P.; Wu, S.; Chung, R.; et al. Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. Mol. Cancer Res. 2014, 12, 1055–1066.
-
(2014)
Cancer Res
, vol.12
, pp. 1055-1066
-
-
Muvaffak, A.1
Pan, Q.2
Yan, H.3
Fernandez, R.4
Lim, J.5
Dolinski, B.6
Nguyen, T.T.7
Strack, P.8
Wu, S.9
Chung, R.10
-
71
-
-
84958891287
-
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression
-
Hayes, T.K.; Neel, N.F.; Hu, C.; Gautam, P.; Chenard, M.; Long, B.; Aziz, M.; Kassner, M.; Bryant, K.L.; Pierobon, M.; et al. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer Cell 2016, 29, 75–89.
-
(2016)
Cancer Cell
, vol.29
, pp. 75-89
-
-
Hayes, T.K.1
Neel, N.F.2
Hu, C.3
Gautam, P.4
Chenard, M.5
Long, B.6
Aziz, M.7
Kassner, M.8
Bryant, K.L.9
Pierobon, M.10
-
72
-
-
35148869637
-
High-throughput soft agar assay for identification of anticancer compound
-
Anderson, S.N.; Towne, D.L.; Burns, D.J.; Warrior, U. A high-throughput soft agar assay for identification of anticancer compound. J. Biomol. Screen. 2007, 12, 938–945.
-
(2007)
J. Biomol. Screen
, vol.12
, pp. 938-945
-
-
Anderson, S.N.1
Towne, D.L.2
Burns, D.J.3
Warrior, U.A.4
-
73
-
-
70349536006
-
In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nat
-
Meacham, C.E.; Ho, E.E.; Dubrovsky, E.; Gertler, F.B.; Hemann, M.T. In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nat. Genet. 2009, 41, 1133–1137.
-
(2009)
Genet
, vol.41
, pp. 1133-1137
-
-
Meacham, C.E.1
Ho, E.E.2
Dubrovsky, E.3
Gertler, F.B.4
Hemann, M.T.5
-
74
-
-
80051923932
-
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer
-
Possemato, R.; Marks, K.M.; Shaul, Y.D.; Pacold, M.E.; Kim, D.; Birsoy, K.; Sethumadhavan, S.; Woo, H.K.; Jang, H.G.; Jha, A.K.; et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011, 476, 346–350.
-
(2011)
Nature
, vol.476
, pp. 346-350
-
-
Possemato, R.1
Marks, K.M.2
Shaul, Y.D.3
Pacold, M.E.4
Kim, D.5
Birsoy, K.6
Sethumadhavan, S.7
Woo, H.K.8
Jang, H.G.9
Jha, A.K.10
-
75
-
-
80054936061
-
Inhibition of Ras for cancer treatment: The search continues
-
Baines, A.T.; Xu, D.; Der, C.J. Inhibition of Ras for cancer treatment: The search continues. Future Med. Chem. 2011, 3, 1787–1808.
-
(2011)
Future Med. Chem.
, vol.3
, pp. 1787-1808
-
-
Baines, A.T.1
Xu, D.2
Der, C.J.3
-
76
-
-
30944447568
-
The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions
-
Yoon, S.; Seger, R. The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions. Growth Factors 2006, 24, 21–44.
-
(2006)
Growth Factors
, vol.24
, pp. 21-44
-
-
Yoon, S.1
Seger, R.2
-
77
-
-
84862294189
-
ERK1/2 MAP kinases: Structure, function, and regulation
-
Roskoski, R. ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacol. Res. 2012, 66, 105–143.
-
(2012)
Pharmacol. Res
, vol.66
, pp. 105-143
-
-
Roskoski, R.1
-
78
-
-
77949685981
-
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
-
Hatzivassiliou, G.; Song, K.; Yen, I.; Brandhuber, B.J.; Anderson, D.J.; Alvarado, R.; Ludlam, M.J.; Stokoe, D.; Gloor, S.L.; Vigers, G.; et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464, 431–435.
-
(2010)
Nature
, vol.464
, pp. 431-435
-
-
Hatzivassiliou, G.1
Song, K.2
Yen, I.3
Brandhuber, B.J.4
Anderson, D.J.5
Alvarado, R.6
Ludlam, M.J.7
Stokoe, D.8
Gloor, S.L.9
Vigers, G.10
-
79
-
-
74849109743
-
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
-
Heidorn, S.J.; Milagre, C.; Whittaker, S.; Nourry, A.; Niculescu-Duvas, I.; Dhomen, N.; Hussain, J.; Reis-Filho, J.S.; Springer, C.J.; Pritchard, C.; et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140, 209–221.
-
(2010)
Cell
, vol.140
, pp. 209-221
-
-
Heidorn, S.J.1
Milagre, C.2
Whittaker, S.3
Nourry, A.4
Niculescu-Duvas, I.5
Dhomen, N.6
Hussain, J.7
Reis-Filho, J.S.8
Springer, C.J.9
Pritchard, C.10
-
80
-
-
77949732073
-
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
-
Poulikakos, P.I.; Zhang, C.; Bollag, G.; Shokat, K.M.; Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464, 427–430.
-
(2010)
Nature
, vol.464
, pp. 427-430
-
-
Poulikakos, P.I.1
Zhang, C.2
Bollag, G.3
Shokat, K.M.4
Rosen, N.5
-
81
-
-
84921270388
-
Targeting RAS-ERK signalling in cancer: Promises and challenges
-
Samatar, A.A.; Poulikakos, P.I. Targeting RAS-ERK signalling in cancer: Promises and challenges. Nat. Rev. Drug Discov. 2014, 13, 928–942.
-
(2014)
Nat. Rev. Drug Discov
, vol.13
, pp. 928-942
-
-
Samatar, A.A.1
Poulikakos, P.I.2
-
82
-
-
84957811485
-
Targeting RAS-mutant Cancers: Is ERK the Key?
-
Ryan, M.B.; Der, C.J.; Wang-Gillam, A.; Cox, A.D. Targeting RAS-mutant Cancers: Is ERK the Key? Trends Cancer 2015, 1, 183–198.
-
(2015)
Trends Cancer
, vol.1
, pp. 183-198
-
-
Ryan, M.B.1
Der, C.J.2
Wang-Gillam, A.3
Cox, A.D.4
-
83
-
-
84942323259
-
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
-
Peng, S.B.; Henry, J.R.; Kaufman, M.D.; Lu, W.P.; Smith, B.D.; Vogeti, S.; Rutkoski, T.J.; Wise, S.; Chun, L.; Zhang, Y.; et al. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Cancer Cell 2015, 28, 384–398.
-
(2015)
Cancer Cell
, vol.28
, pp. 384-398
-
-
Peng, S.B.1
Henry, J.R.2
Kaufman, M.D.3
Lu, W.P.4
Smith, B.D.5
Vogeti, S.6
Rutkoski, T.J.7
Wise, S.8
Chun, L.9
Zhang, Y.10
-
84
-
-
84945243598
-
RAF inhibitors that evade paradoxical MAPK pathway activation
-
Zhang, C.; Spevak, W.; Zhang, Y.; Burton, E.A.; Ma, Y.; Habets, G.; Zhang, J.; Lin, J.; Ewing, T.; Matusow, B.; et al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature 2015, 526, 583–586.
-
(2015)
Nature
, vol.526
, pp. 583-586
-
-
Zhang, C.1
Spevak, W.2
Zhang, Y.3
Burton, E.A.4
Ma, Y.5
Habets, G.6
Zhang, J.7
Lin, J.8
Ewing, T.9
-
85
-
-
84940020969
-
Trametinib: A MEK inhibitor for management of metastatic melanoma
-
Lugowska, I.; Koseła-Paterczyk, H.; Kozak, K.; Rutkowski, P. Trametinib: A MEK inhibitor for management of metastatic melanoma. Onco. Targets Ther. 2015, 8, 2251–2259.
-
(2015)
Onco. Targets Ther
, vol.8
, pp. 2251-2259
-
-
Lugowska, I.1
Koseła-Paterczyk, H.2
Kozak, K.3
Rutkowski, P.4
-
86
-
-
79952261716
-
GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition
-
Gilmartin, A.G.; Bleam, M.R.; Groy, A.; Moss, K.G.; Minthorn, E.A.; Kulkarni, S.G.; Rominger, C.M.; Erskine, S.; Fisher, K.E.; Yang, J.; et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 2011, 17, 989–1000.
-
(2011)
Clin. Cancer Res
, vol.17
, pp. 989-1000
-
-
Gilmartin, A.G.1
Bleam, M.R.2
Groy, A.3
Moss, K.G.4
Minthorn, E.A.5
Kulkarni, S.G.6
Rominger, C.M.7
Erskine, S.8
Fisher, K.E.9
Yang, J.10
-
87
-
-
57349194139
-
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
-
Engelman, J.A.; Chen, L.; Tan, X.; Crosby, K.; Guimaraes, A.R.; Upadhyay, R.; Maira, M.; McNamara, K.; Perera, S.A.; Song, Y.; et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14, 1351–1356.
-
(2008)
Nat. Med
, vol.14
, pp. 1351-1356
-
-
Engelman, J.A.1
Chen, L.2
Tan, X.3
Crosby, K.4
Guimaraes, A.R.5
Upadhyay, R.6
Maira, M.7
McNamara, K.8
Perera, S.A.9
Song, Y.10
-
88
-
-
84884127318
-
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
-
Hatzivassiliou, G.; Haling, J.R.; Chen, H.; Song, K.; Price, S.; Heald, R.; Hewitt, J.F.; Zak, M.; Peck, A.; Orr, C.; et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature 2013, 501, 232–236.
-
(2013)
Nature
, vol.501
, pp. 232-236
-
-
Hatzivassiliou, G.1
Haling, J.R.2
Chen, H.3
Song, K.4
Price, S.5
Heald, R.6
Hewitt, J.F.7
Zak, M.8
Peck, A.9
Orr, C.10
-
89
-
-
84859765844
-
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer
-
Duncan, J.S.; Whittle, M.C.; Nakamura, K.; Abell, A.N.; Midland, A.A.; Zawistowski, J.S.; Johnson, N.L.; Granger, D.A.; Jordan, N.V.; Darr, D.B.; et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149, 307–321.
-
(2012)
Cell
, vol.149
, pp. 307-321
-
-
Duncan, J.S.1
Whittle, M.C.2
Nakamura, K.3
Abell, A.N.4
Midland, A.A.5
Zawistowski, J.S.6
Johnson, N.L.7
Granger, D.A.8
Jordan, N.V.9
Darr, D.B.10
-
90
-
-
84880254869
-
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors
-
Morris, E.J.; Jha, S.; Restaino, C.R.; Dayananth, P.; Zhu, H.; Cooper, A.; Carr, D.; Deng, Y.; Jin, W.; Black, S.; et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013, 3, 742–750.
-
(2013)
Cancer Discov
, vol.3
, pp. 742-750
-
-
Morris, E.J.1
Jha, S.2
Restaino, C.R.3
Dayananth, P.4
Zhu, H.5
Cooper, A.6
Carr, D.7
Deng, Y.8
Jin, W.9
Black, S.10
-
91
-
-
84893249799
-
PI3K and cancer: Lessons, challenges and opportunities
-
Fruman, D.A.; Rommel, C. PI3K and cancer: Lessons, challenges and opportunities. Nat. Rev. Drug Discov. 2014, 13, 140–156.
-
(2014)
Nat. Rev. Drug Discov
, vol.13
, pp. 140-156
-
-
Fruman, D.A.1
Rommel, C.2
-
92
-
-
67749122122
-
Targeting PI3K signalling in cancer: Opportunities, challenges and limitations
-
Engelman, J.A. Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9, 550–562.
-
(2009)
Nat. Rev. Cancer
, vol.9
, pp. 550-562
-
-
Engelman, J.A.1
-
93
-
-
84943271871
-
PI3K isoform-selective inhibitors: Next-generation targeted cancer therapies
-
Wang, X.; Ding, J.; Meng, L.H. PI3K isoform-selective inhibitors: Next-generation targeted cancer therapies. Acta Pharmacol. Sin. 2015, 36, 1170–1176.
-
(2015)
Acta Pharmacol. Sin
, vol.36
, pp. 1170-1176
-
-
Wang, X.1
Ding, J.2
Meng, L.H.3
-
94
-
-
61349141302
-
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2
-
Feldman, M.E.; Apsel, B.; Uotila, A.; Loewith, R.; Knight, Z.A.; Ruggero, D.; Shokat, K.M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009.
-
(2009)
Plos Biol
-
-
Feldman, M.E.1
Apsel, B.2
Uotila, A.3
Loewith, R.4
Knight, Z.A.5
Ruggero, D.6
Shokat, K.M.7
-
95
-
-
65549145048
-
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1
-
Thoreen, C.C.; Kang, S.A.; Chang, J.W.; Liu, Q.; Zhang, J.; Gao, Y.; Reichling, L.J.; Sim, T.; Sabatini, D.M.; Gray, N.S. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 2009, 284, 8023–8032.
-
(2009)
J. Biol. Chem
, vol.284
, pp. 8023-8032
-
-
Thoreen, C.C.1
Kang, S.A.2
Chang, J.W.3
Liu, Q.4
Zhang, J.5
Gao, Y.6
Reichling, L.J.7
Sim, T.8
Sabatini, D.M.9
Gray, N.S.10
-
96
-
-
51849098272
-
Drug discovery approaches targeting the PI3K/Akt pathway in cancer
-
Garcia-Echeverria, C.; Sellers, W.R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008, 27, 5511–5526.
-
(2008)
Oncogene
, vol.27
, pp. 5511-5526
-
-
Garcia-Echeverria, C.1
Sellers, W.R.2
-
97
-
-
84876437832
-
Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer
-
Eser, S.; Reiff, N.; Messer, M.; Seidler, B.; Gottschalk, K.; Dobler, M.; Hieber, M.; Arbeiter, A.; Klein, S.; Kong, B.; et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 2013, 23, 406–420.
-
(2013)
Cancer Cell
, vol.23
, pp. 406-420
-
-
Eser, S.1
Reiff, N.2
Messer, M.3
Seidler, B.4
Gottschalk, K.5
Dobler, M.6
Hieber, M.7
Arbeiter, A.8
Klein, S.9
Kong, B.10
-
98
-
-
77949681661
-
Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor
-
Meuillet, E.J.; Zuohe, S.; Lemos, R.; Ihle, N.; Kingston, J.; Watkins, R.; Moses, S.A.; Zhang, S.; Du-Cuny, L.; Herbst, R.; et al. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol. Cancer Ther. 2010, 9, 706–717.
-
(2010)
Mol. Cancer Ther
, vol.9
, pp. 706-717
-
-
Meuillet, E.J.1
Zuohe, S.2
Lemos, R.3
Ihle, N.4
Kingston, J.5
Watkins, R.6
Moses, S.A.7
Zhang, S.8
Du-Cuny, L.9
Herbst, R.10
-
99
-
-
84959244390
-
Improved Treatment of Pancreatic Cancer With Drug Delivery Nanoparticles Loaded With a Novel AKT/PDK1 Inhibitor
-
Kobes, J.E.; Daryaei, I.; Howison, C.M.; Bontrager, J.G.; Sirianni, R.W.; Meuillet, E.J.; Pagel, M.D. Improved Treatment of Pancreatic Cancer With Drug Delivery Nanoparticles Loaded With a Novel AKT/PDK1 Inhibitor. Pancreas 2016.
-
(2016)
Pancreas
-
-
Kobes, J.E.1
Daryaei, I.2
Howison, C.M.3
Bontrager, J.G.4
Sirianni, R.W.5
Meuillet, E.J.6
Pagel, M.D.7
-
100
-
-
84921296898
-
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer
-
Junttila, M.R.; Devasthali, V.; Cheng, J.H.; Castillo, J.; Metcalfe, C.; Clermont, A.C.; Otter, D.D.; Chan, E.; Bou-Reslan, H.; Cao, T.; et al. Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer. Mol. Cancer Ther. 2015, 14, 40–47.
-
(2015)
Mol. Cancer Ther
, vol.14
, pp. 40-47
-
-
Junttila, M.R.1
Devasthali, V.2
Cheng, J.H.3
Castillo, J.4
Metcalfe, C.5
Clermont, A.C.6
Otter, D.D.7
Chan, E.8
Bou-Reslan, H.9
Cao, T.10
-
101
-
-
84866242663
-
A central role for RAFÑMEKÑERK signaling in the genesis of pancreatic ductal adenocarcinoma
-
Collisson, E.A.; Trejo, C.L.; Silva, J.M.; Gu, S.; Korkola, J.E.; Heiser, L.M.; Charles, R.P.; Rabinovich, B.A.; Hann, B.; Dankort, D.; et al. A central role for RAFÑMEKÑERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2012, 2, 685–693.
-
(2012)
Cancer Discov
, vol.2
, pp. 685-693
-
-
Collisson, E.A.1
Trejo, C.L.2
Silva, J.M.3
Gu, S.4
Korkola, J.E.5
Heiser, L.M.6
Charles, R.P.7
Rabinovich, B.A.8
Hann, B.9
Dankort, D.10
-
102
-
-
84878652051
-
PI3K and MEK inhibitor combinations: Examining the evidence in selected tumor types
-
Britten, C.D. PI3K and MEK inhibitor combinations: Examining the evidence in selected tumor types. Cancer Chemother. Pharmacol. 2013, 71, 1395–1409.
-
(2013)
Cancer Chemother. Pharmacol
, vol.71
, pp. 1395-1409
-
-
Britten, C.D.1
-
103
-
-
34548189038
-
ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms
-
Kong, D.; Yamori, T. ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Cancer Sci. 2007, 98, 1638–1642.
-
(2007)
Cancer Sci
, vol.98
, pp. 1638-1642
-
-
Kong, D.1
Yamori, T.2
-
104
-
-
84925483104
-
Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor
-
Van Dort, M.E.; Galbán, S.; Wang, H.; Sebolt-Leopold, J.; Whitehead, C.; Hong, H.; Rehemtulla, A.; Ross, B.D. Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor. Bioorg. Med. Chem. 2015, 23, 1386–1394.
-
(2015)
Bioorg. Med. Chem.
, vol.23
, pp. 1386-1394
-
-
Van Dort, M.E.1
Galbán, S.2
Wang, H.3
Sebolt-Leopold, J.4
Whitehead, C.5
Hong, H.6
Rehemtulla, A.7
Ross, B.D.8
-
105
-
-
84856655854
-
Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells
-
Zhou, W.; Capello, M.; Fredolini, C.; Racanicchi, L.; Piemonti, L.; Liotta, L.A.; Novelli, F.; Petricoin, E.F. Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. J. Proteome Res. 2012, 11, 554–563.
-
(2012)
J. Proteome Res
, vol.11
, pp. 554-563
-
-
Zhou, W.1
Capello, M.2
Fredolini, C.3
Racanicchi, L.4
Piemonti, L.5
Liotta, L.A.6
Novelli, F.7
Petricoin, E.F.8
-
106
-
-
76649126249
-
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
-
Le, A.; Cooper, C.R.; Gouw, A.M.; Dinavahi, R.; Maitra, A.; Deck, L.M.; Royer, R.E.; Vander Jagt, D.L.; Semenza, G.L.; Dang, C.V. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. USA 2010, 107, 2037–2042.
-
(2010)
Proc. Natl. Acad. Sci. USA
, vol.107
, pp. 2037-2042
-
-
Le, A.1
Cooper, C.R.2
Gouw, A.M.3
Dinavahi, R.4
Maitra, A.5
Deck, L.M.6
Royer, R.E.7
Vander Jagt, D.L.8
Semenza, G.L.9
Dang, C.V.10
-
107
-
-
84881557242
-
Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer
-
Patra, K.C.; Wang, Q.; Bhaskar, P.T.; Miller, L.; Wang, Z.; Wheaton, W.; Chandel, N.; Laakso, M.; Muller, W.J.; Allen, E.L.; et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 2013, 24, 213–228.
-
(2013)
Cancer Cell
, vol.24
, pp. 213-228
-
-
Patra, K.C.1
Wang, Q.2
Bhaskar, P.T.3
Miller, L.4
Wang, Z.5
Wheaton, W.6
Chandel, N.7
Laakso, M.8
Muller, W.J.9
Allen, E.L.10
-
108
-
-
4744341871
-
Advanced cancers: Eradication in all cases using 3-bromopyruvate therapy to deplete ATP
-
Ko, Y.H.; Smith, B.L.; Wang, Y.; Pomper, M.G.; Rini, D.A.; Torbenson, M.S.; Hullihen, J.; Pedersen, P.L. Advanced cancers: Eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem. Biophys. Res. Commun. 2004, 324, 269–275.
-
(2004)
Biochem. Biophys. Res. Commun
, vol.324
, pp. 269-275
-
-
Ko, Y.H.1
Smith, B.L.2
Wang, Y.3
Pomper, M.G.4
Rini, D.A.5
Torbenson, M.S.6
Hullihen, J.7
Pedersen, P.L.8
-
109
-
-
84862809596
-
A translational study “case report” on the small molecule “energy blocker” 3-bromopyruvate (3BP) as a potent anticancer agent: From bench side to bedside
-
Ko, Y.H.; Verhoeven, H.A.; Lee, M.J.; Corbin, D.J.; Vogl, T.J.; Pedersen, P.L. A translational study “case report” on the small molecule “energy blocker” 3-bromopyruvate (3BP) as a potent anticancer agent: From bench side to bedside. J. Bioenerg. Biomembr. 2012, 44, 163–170.
-
(2012)
J. Bioenerg. Biomembr
, vol.44
, pp. 163-170
-
-
Ko, Y.H.1
Verhoeven, H.A.2
Lee, M.J.3
Corbin, D.J.4
Vogl, T.J.5
Pedersen, P.L.6
-
110
-
-
77955281020
-
Glutamine addiction: A new therapeutic target in cancer
-
Wise, D.R.; Thompson, C.B. Glutamine addiction: A new therapeutic target in cancer. Trends Biochem. Sci. 2010, 35, 427–433.
-
(2010)
Trends Biochem. Sci
, vol.35
, pp. 427-433
-
-
Wise, D.R.1
Thompson, C.B.2
-
111
-
-
84883497454
-
Glutamine and cancer: Cell biology, physiology, and clinical opportunities
-
Hensley, C.T.; Wasti, A.T.; DeBerardinis, R.J. Glutamine and cancer: Cell biology, physiology, and clinical opportunities. J. Clin. Investig. 2013, 123, 3678–3684.
-
(2013)
J. Clin. Investig
, vol.123
, pp. 3678-3684
-
-
Hensley, C.T.1
Wasti, A.T.2
Deberardinis, R.J.3
-
112
-
-
84908192544
-
The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation
-
Csibi, A.; Lee, G.; Yoon, S.O.; Tong, H.; Ilter, D.; Elia, I.; Fendt, S.M.; Roberts, T.M.; Blenis, J. The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation. Curr. Biol. 2014, 24, 2274–2280.
-
(2014)
Curr. Biol
, vol.24
, pp. 2274-2280
-
-
Csibi, A.1
Lee, G.2
Yoon, S.O.3
Tong, H.4
Ilter, D.5
Elia, I.6
Fendt, S.M.7
Roberts, T.M.8
Blenis, J.9
-
113
-
-
84875894714
-
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
-
Son, J.; Lyssiotis, C.A.; Ying, H.; Wang, X.; Hua, S.; Ligorio, M.; Perera, R.M.; Ferrone, C.R.; Mullarky, E.; Shyh-Chang, N.; et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013, 496, 101–105.
-
(2013)
Nature
, vol.496
, pp. 101-105
-
-
Son, J.1
Lyssiotis, C.A.2
Ying, H.3
Wang, X.4
Hua, S.5
Ligorio, M.6
Perera, R.M.7
Ferrone, C.R.8
Mullarky, E.9
Shyh-Chang, N.10
-
114
-
-
0025232412
-
Metabolism and action of amino acid analog anti-cancer agents
-
Ahluwalia, G.S.; Grem, J.L.; Hao, Z.; Cooney, D.A. Metabolism and action of amino acid analog anti-cancer agents. Pharmacol. Ther. 1990, 46, 243–271.
-
(1990)
Pharmacol. Ther
, vol.46
, pp. 243-271
-
-
Ahluwalia, G.S.1
Grem, J.L.2
Hao, Z.3
Cooney, D.A.4
-
115
-
-
77957937428
-
Targeting mitochondrial glutaminase activity inhibits oncogenic transformation
-
Wang, J.B.; Erickson, J.W.; Fuji, R.; Ramachandran, S.; Gao, P.; Dinavahi, R.; Wilson, K.F.; Ambrosio, A.L.; Dias, S.M.; Dang, C.V.; et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010, 18, 207–219.
-
(2010)
Cancer Cell
, vol.18
, pp. 207-219
-
-
Wang, J.B.1
Erickson, J.W.2
Fuji, R.3
Ramachandran, S.4
Gao, P.5
Dinavahi, R.6
Wilson, K.F.7
Ambrosio, A.L.8
Dias, S.M.9
Dang, C.V.10
-
116
-
-
34548789512
-
Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES)
-
Robinson, M.M.; McBryant, S.J.; Tsukamoto, T.; Rojas, C.; Ferraris, D.V.; Hamilton, S.K.; Hansen, J.C.; Curthoys, N.P. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem. J. 2007, 406, 407–414.
-
(2007)
Biochem. J
, vol.406
, pp. 407-414
-
-
Robinson, M.M.1
McBryant, S.J.2
Tsukamoto, T.3
Rojas, C.4
Ferraris, D.V.5
Hamilton, S.K.6
Hansen, J.C.7
Curthoys, N.P.8
-
117
-
-
84879766148
-
Pancreatic cancers rely on a novel glutamine metabolism pathway to maintain redox balance
-
Lyssiotis, C.A.; Son, J.; Cantley, L.C.; Kimmelman, A.C. Pancreatic cancers rely on a novel glutamine metabolism pathway to maintain redox balance. Cell Cycle 2013, 12, 1987–1988.
-
(2013)
Cell Cycle
, vol.12
, pp. 1987-1988
-
-
Lyssiotis, C.A.1
Son, J.2
Cantley, L.C.3
Kimmelman, A.C.4
-
118
-
-
84885357137
-
Exploiting the bad eating habits of Ras-driven cancers
-
White, E. Exploiting the bad eating habits of Ras-driven cancers. Genes Dev. 2013, 27, 2065–2071.
-
(2013)
Genes Dev
, vol.27
, pp. 2065-2071
-
-
White, E.1
-
119
-
-
84878396462
-
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
-
Commisso, C.; Davidson, S.M.; Soydaner-Azeloglu, R.G.; Parker, S.J.; Kamphorst, J.J.; Hackett, S.; Grabocka, E.; Nofal, M.; Drebin, J.A.; Thompson, C.B.; et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 2013, 497, 633–637.
-
(2013)
Nature
, vol.497
, pp. 633-637
-
-
Commisso, C.1
Davidson, S.M.2
Soydaner-Azeloglu, R.G.3
Parker, S.J.4
Kamphorst, J.J.5
Hackett, S.6
Grabocka, E.7
Nofal, M.8
Drebin, J.A.9
Thompson, C.B.10
-
120
-
-
84937253537
-
The utilization of extracellular proteins as nutrients is suppressed by mTORC1
-
Palm, W.; Park, Y.; Wright, K.; Pavlova, N.N.; Tuveson, D.A.; Thompson, C.B. The utilization of extracellular proteins as nutrients is suppressed by mTORC1. Cell 2015, 162, 259–270.
-
(2015)
Cell
, vol.162
, pp. 259-270
-
-
Palm, W.1
Park, Y.2
Wright, K.3
Pavlova, N.N.4
Tuveson, D.A.5
Thompson, C.B.6
-
121
-
-
84961288972
-
Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein
-
Kamphorst, J.J.; Nofal, M.; Commisso, C.; Hackett, S.R.; Lu, W.; Grabocka, E.; Vander Heiden, M.G.; Miller, G.; Drebin, J.A.; Bar-Sagi, D.; et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 2015, 75, 544–553.
-
(2015)
Cancer Res.
, vol.75
, pp. 544-553
-
-
Kamphorst, J.J.1
Nofal, M.2
Commisso, C.3
Hackett, S.R.4
Lu, W.5
Grabocka, E.6
Vander Heiden, M.G.7
Miller, G.8
Drebin, J.A.9
Bar-Sagi, D.10
-
122
-
-
78649704325
-
Autophagy and metabolism
-
Rabinowitz, J.D.; White, E. Autophagy and metabolism. Science 2010, 330, 1344–1348.
-
(2010)
Science
, vol.330
, pp. 1344-1348
-
-
Rabinowitz, J.D.1
White, E.2
-
123
-
-
33750284176
-
Autophagy in cancer: Good, bad, or both?
-
Hippert, M.M.; O'Toole, P.S.; Thorburn, A. Autophagy in cancer: Good, bad, or both? Cancer Res. 2006, 66, 9349–9351.
-
(2006)
Cancer Res
, vol.66
, pp. 9349-9351
-
-
Hippert, M.M.1
O'toole, P.S.2
Thorburn, A.3
-
124
-
-
50149095124
-
Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome
-
Fujii, S.; Mitsunaga, S.; Yamazaki, M.; Hasebe, T.; Ishii, G.; Kojima, M.; Kinoshita, T.; Ueno, T.; Esumi, H.; Ochiai, A. Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Sci. 2008, 99, 1813–1819.
-
(2008)
Cancer Sci
, vol.99
, pp. 1813-1819
-
-
Fujii, S.1
Mitsunaga, S.2
Yamazaki, M.3
Hasebe, T.4
Ishii, G.5
Kojima, M.6
Kinoshita, T.7
Ueno, T.8
Esumi, H.9
Ochiai, A.10
-
125
-
-
79952229430
-
Pancreatic cancers require autophagy for tumor growth
-
Yang, S.; Wang, X.; Contino, G.; Liesa, M.; Sahin, E.; Ying, H.; Bause, A.; Li, Y.; Stommel, J.M.; Dell’antonio, G.; et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011, 25, 717–729.
-
(2011)
Genes Dev
, vol.25
, pp. 717-729
-
-
Yang, S.1
Wang, X.2
Contino, G.3
Liesa, M.4
Sahin, E.5
Ying, H.6
Bause, A.7
Li, Y.8
Stommel, J.M.9
-
126
-
-
79952228407
-
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
-
Guo, J.Y.; Chen, H.Y.; Mathew, R.; Fan, J.; Strohecker, A.M.; Karsli-Uzunbas, G.; Kamphorst, J.J.; Chen, G.; Lemons, J.M.; Karantza, V.; et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 2011, 25, 460–470.
-
(2011)
Genes Dev
, vol.25
, pp. 460-470
-
-
Guo, J.Y.1
Chen, H.Y.2
Mathew, R.3
Fan, J.4
Strohecker, A.M.5
Karsli-Uzunbas, G.6
Kamphorst, J.J.7
Chen, G.8
Lemons, J.M.9
Karantza, V.10
-
127
-
-
79953306808
-
Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival
-
Elgendy, M.; Sheridan, C.; Brumatti, G.; Martin, S.J. Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. Mol. Cell 2011, 42, 23–35.
-
(2011)
Mol. Cell
, vol.42
, pp. 23-35
-
-
Elgendy, M.1
Sheridan, C.2
Brumatti, G.3
Martin, S.J.4
-
128
-
-
64349123107
-
Autophagy mediates the mitotic senescence transition
-
Young, A.R.; Narita, M.; Ferreira, M.; Kirschner, K.; Sadaie, M.; Darot, J.F.; Tavaré, S.; Arakawa, S.; Shimizu, S.; Watt, F.M.; et al. Autophagy mediates the mitotic senescence transition. Genes Dev. 2009, 23, 798–803.
-
(2009)
Genes Dev
, vol.23
, pp. 798-803
-
-
Young, A.R.1
Narita, M.2
Ferreira, M.3
Kirschner, K.4
Sadaie, M.5
Darot, J.F.6
Tavaré, S.7
Arakawa, S.8
Shimizu, S.9
-
129
-
-
84953274881
-
Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy
-
Eng, C.H.; Wang, Z.; Tkach, D.; Toral-Barza, L.; Ugwonali, S.; Liu, S.; Fitzgerald, S.L.; George, E.; Frias, E.; Cochran, N.; et al. Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy. Proc. Natl. Acad. Sci. USA 2016, 113, 182–187.
-
(2016)
Proc. Natl. Acad. Sci. USA
, vol.113
, pp. 182-187
-
-
Eng, C.H.1
Wang, Z.2
Tkach, D.3
Toral-Barza, L.4
Ugwonali, S.5
Liu, S.6
Fitzgerald, S.L.7
George, E.8
Frias, E.9
Cochran, N.10
-
130
-
-
84890432985
-
P53 status determines the role of autophagy in pancreatic tumour development
-
Rosenfeldt, M.T.; O'Prey, J.; Morton, J.P.; Nixon, C.; MacKay, G.; Mrowinska, A.; Au, A.; Rai, T.S.; Zheng, L.; Ridgway, R.; et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature 2013, 504, 296–300.
-
(2013)
Nature
, vol.504
, pp. 296-300
-
-
Rosenfeldt, M.T.1
O'prey, J.2
Morton, J.P.3
Nixon, C.4
Mackay, G.5
Mrowinska, A.6
Au, A.7
Rai, T.S.8
Zheng, L.9
Ridgway, R.10
-
131
-
-
84905499163
-
Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations
-
Yang, A.; Rajeshkumar, N.V.; Wang, X.; Yabuuchi, S.; Alexander, B.M.; Chu, G.C.; Hoff Von, D.D.; Maitra, A.; Kimmelman, A.C. Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov. 2014, 4, 905–913.
-
(2014)
Cancer Discov
, vol.4
, pp. 905-913
-
-
Yang, A.1
Rajeshkumar, N.V.2
Wang, X.3
Yabuuchi, S.4
Alexander, B.M.5
Chu, G.C.6
Hoff Von, D.D.7
Maitra, A.8
Kimmelman, A.C.9
-
132
-
-
84901933891
-
Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma
-
Wolpin, B.M.; Rubinson, D.A.; Wang, X.; Chan, J.A.; Cleary, J.M.; Enzinger, P.C.; Fuchs, C.S.; McCleary, N.J.; Meyerhardt, J.A.; Ng, K.; et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist 2014, 19, 637–638.
-
(2014)
Oncologist
, vol.19
, pp. 637-638
-
-
Wolpin, B.M.1
Rubinson, D.A.2
Wang, X.3
Chan, J.A.4
Cleary, J.M.5
Enzinger, P.C.6
Fuchs, C.S.7
McCleary, N.J.8
Meyerhardt, J.A.9
Ng, K.10
-
133
-
-
77958050577
-
Phase 2 trial of single agent Ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma
-
Royal, R.E.; Levy, C.; Turner, K.; Mathur, A.; Hughes, M.; Kammula, U.S.; Sherry, R.M.; Topalian, S.L.; Yang, J.C.; Lowy, I.; et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 2010, 33, 828–833.
-
(2010)
J. Immunother
, vol.33
, pp. 828-833
-
-
Royal, R.E.1
Levy, C.2
Turner, K.3
Mathur, A.4
Hughes, M.5
Kammula, U.S.6
Sherry, R.M.7
Topalian, S.L.8
Yang, J.C.9
Lowy, I.10
-
134
-
-
84877052290
-
Inflammatory networks and immune surveillance of pancreatic carcinoma
-
Vonderheide, R.H.; Bayne, L.J. Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr. Opin. Immunol. 2013, 25, 200–205.
-
(2013)
Curr. Opin. Immunol
, vol.25
, pp. 200-205
-
-
Vonderheide, R.H.1
Bayne, L.J.2
-
135
-
-
0029886683
-
Multiple levels of MHC class I down-regulation by RAS oncogenes
-
Lohmann, S.; Wollscheid, U.; Huber, C.; Seliger, B. Multiple levels of MHC class I down-regulation by RAS oncogenes. Scand. J. Immunol. 1996, 43, 537–544.
-
(1996)
Scand. J. Immunol
, vol.43
, pp. 537-544
-
-
Lohmann, S.1
Wollscheid, U.2
Huber, C.3
Seliger, B.4
-
136
-
-
0029967963
-
Suppression of MHC class I antigens in oncogenic transformants: Association with decreased recognition by cytotoxic T lymphocytes
-
Seliger, B.; Harders, C.; Wollscheid, U.; Staege, M.S.; Reske-Kunz, A.B.; Huber, C. Suppression of MHC class I antigens in oncogenic transformants: Association with decreased recognition by cytotoxic T lymphocytes. Exp. Hematol. 1996, 24, 1275–1279.
-
(1996)
Exp. Hematol.
, vol.24
, pp. 1275-1279
-
-
Seliger, B.1
Harders, C.2
Wollscheid, U.3
Staege, M.S.4
Reske-Kunz, A.B.5
Huber, C.6
-
137
-
-
0031964480
-
Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts
-
Seliger, B.; Harders, C.; Lohmann, S.; Momburg, F.; Urlinger, S.; Tampé, R.; Huber, C. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur. J. Immunol. 1998, 28, 122–133.
-
(1998)
Eur. J. Immunol
, vol.28
, pp. 122-133
-
-
Seliger, B.1
Harders, C.2
Lohmann, S.3
Momburg, F.4
Urlinger, S.5
Tampé, R.6
Huber, C.7
-
138
-
-
0033945925
-
Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin
-
Delp, K.; Momburg, F.; Hilmes, C.; Huber, C.; Seliger, B. Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin. Bone Marrow Transplant. 2000, 25, 88–95.
-
(2000)
Bone Marrow Transplant
, vol.25
, pp. 88-95
-
-
Delp, K.1
Momburg, F.2
Hilmes, C.3
Huber, C.4
Seliger, B.5
-
139
-
-
0025752591
-
Reduced stimulation of helper T cells by Ki-RAS transformed cells
-
Maudsley, D.J.; Bateman, W.J.; Morris, A.G. Reduced stimulation of helper T cells by Ki-RAS transformed cells. Immunology 1991, 72, 277–281.
-
(1991)
Immunology
, vol.72
, pp. 277-281
-
-
Maudsley, D.J.1
Bateman, W.J.2
Morris, A.G.3
-
140
-
-
12644289322
-
Dacarbazine-induced immunogenicity of a murine leukemia is attenuated in cells transfected with mutated K-ras gene
-
Testorelli, C.; Bussini, S.; De Filippi, R.; Marelli, O.; Orlando, L.; Greiner, J.W.; Grohmann, U.; Tentori, L.; Giuliani, A.; Bonmassar, E.; et al. Dacarbazine-induced immunogenicity of a murine leukemia is attenuated in cells transfected with mutated K-ras gene. J. Exp. Clin. Cancer Res. 1997, 16, 15–22.
-
(1997)
J. Exp. Clin. Cancer Res.
, vol.16
, pp. 15-22
-
-
Testorelli, C.1
Bussini, S.2
De Filippi, R.3
Marelli, O.4
Orlando, L.5
Greiner, J.W.6
Grohmann, U.7
Tentori, L.8
Giuliani, A.9
Bonmassar, E.10
-
141
-
-
7944223098
-
Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis
-
Sparmann, A.; Bar-Sagi, D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004, 6, 447–458.
-
(2004)
Cancer Cell
, vol.6
, pp. 447-458
-
-
Sparmann, A.1
Bar-Sagi, D.2
-
142
-
-
84862147254
-
Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia
-
Pylayeva-Gupta, Y.; Lee, K.E.; Hajdu, C.H.; Miller, G.; Bar-Sagi, D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 2012, 21, 836–847.
-
(2012)
Cancer Cell
, vol.21
, pp. 836-847
-
-
Pylayeva-Gupta, Y.1
Lee, K.E.2
Hajdu, C.H.3
Miller, G.4
Bar-Sagi, D.5
-
143
-
-
84863393623
-
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma
-
Wilmott, J.S.; Long, G.V.; Howle, J.R.; Haydu, L.E.; Sharma, R.N.; Thompson, J.F.; Kefford, R.F.; Hersey, P.; Scolyer, R.A. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 2012, 18, 1386–1394.
-
(2012)
Clin. Cancer Res
, vol.18
, pp. 1386-1394
-
-
Wilmott, J.S.1
Long, G.V.2
Howle, J.R.3
Haydu, L.E.4
Sharma, R.N.5
Thompson, J.F.6
Kefford, R.F.7
Hersey, P.8
Scolyer, R.A.9
-
144
-
-
84883008576
-
BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer
-
Donia, M.; Fagone, P.; Nicoletti, F.; Andersen, R.S.; Høgdall, E.; Straten, P.T.; Andersen, M.H.; Svane, I.M. BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology 2012, 1, 1476–1483.
-
(2012)
Oncoimmunology
, vol.1
, pp. 1476-1483
-
-
Donia, M.1
Fagone, P.2
Nicoletti, F.3
Andersen, R.S.4
Høgdall, E.5
Straten, P.T.6
Andersen, M.H.7
Svane, I.M.8
-
145
-
-
84872514398
-
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice
-
Liu, C.; Peng, W.; Xu, C.; Lou, Y.; Zhang, M.; Wargo, J.A.; Chen, J.Q.; Li, H.S.; Watowich, S.S.; Yang, Y.; et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin. Cancer Res. 2013, 19, 393–403.
-
(2013)
Clin. Cancer Res.
, vol.19
, pp. 393-403
-
-
Liu, C.1
Peng, W.2
Xu, C.3
Lou, Y.4
Zhang, M.5
Wargo, J.A.6
Chen, J.Q.7
Li, H.S.8
Watowich, S.S.9
Yang, Y.10
-
146
-
-
84962301039
-
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
-
Loi, S.; Dushyanthen, S.; Beavis, P.A.; Salgado, R.; Denkert, C.; Savas, P.; Combs, S.; Rimm, D.L.; Giltnane, J.M.; Estrada, M.V.; et al. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clin. Cancer Res. 2016, 22, 1499–1509.
-
(2016)
Clin. Cancer Res
, vol.22
, pp. 1499-1509
-
-
Loi, S.1
Dushyanthen, S.2
Beavis, P.A.3
Salgado, R.4
Denkert, C.5
Savas, P.6
Combs, S.7
Rimm, D.L.8
Giltnane, J.M.9
Estrada, M.V.10
-
147
-
-
84927666190
-
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
-
Liu, L.; Mayes, P.A.; Eastman, S.; Shi, H.; Yadavilli, S.; Zhang, T.; Yang, J.; Seestaller-Wehr, L.; Zhang, S.Y.; Hopson, C.; et al. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4. Clin. Cancer Res. 2015, 21, 1639–1651.
-
(2015)
Clin. Cancer Res
, vol.21
, pp. 1639-1651
-
-
Liu, L.1
Mayes, P.A.2
Eastman, S.3
Shi, H.4
Yadavilli, S.5
Zhang, T.6
Yang, J.7
Seestaller-Wehr, L.8
Zhang, S.Y.9
Hopson, C.10
-
148
-
-
84855201311
-
Stella TUM: Current consensus and discussion on pancreatic stellate cell research
-
Erkan, M.; Adler, G.; Apte, M.V.; Bachem, M.G.; Buchholz, M.; Detlefsen, S.; Esposito, I.; Friess, H.; Gress, T.M.; Habisch, H.J.; et al. Stella TUM: Current consensus and discussion on pancreatic stellate cell research. Gut 2012, 61, 172–178.
-
(2012)
Gut
, vol.61
, pp. 172-178
-
-
Erkan, M.1
Adler, G.2
Apte, M.V.3
Bachem, M.G.4
Buchholz, M.5
Detlefsen, S.6
Esposito, I.7
Friess, H.8
Gress, T.M.9
Habisch, H.J.10
-
149
-
-
38849141696
-
Cancer-associated stromal fibroblasts promote pancreatic tumor progression
-
Hwang, R.F.; Moore, T.; Arumugam, T.; Ramachandran, V.; Amos, K.D.; Rivera, A.; Ji, B.; Evans, D.B.; Logsdon, C.D. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 2008, 68, 918–926.
-
(2008)
Cancer Res
, vol.68
, pp. 918-926
-
-
Hwang, R.F.1
Moore, T.2
Arumugam, T.3
Ramachandran, V.4
Amos, K.D.5
Rivera, A.6
Ji, B.7
Evans, D.B.8
Logsdon, C.D.9
-
150
-
-
84885187627
-
Understanding the stroma of pancreatic cancer: Co-evolution of the microenvironment with epithelial carcinogenesis
-
Erkan, M. Understanding the stroma of pancreatic cancer: Co-evolution of the microenvironment with epithelial carcinogenesis. J. Pathol. 2013, 231, 4–7.
-
(2013)
J. Pathol
, vol.231
, pp. 4-7
-
-
Erkan, M.1
-
151
-
-
84876153722
-
Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes
-
Kadaba, R.; Birke, H.; Wang, J.; Hooper, S.; Andl, C.D.; Di Maggio, F.; Soylu, E.; Ghallab, M.; Bor, D.; Froeling, F.E.; et al. Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. J. Pathol. 2013, 230, 107–117.
-
(2013)
J. Pathol
, vol.230
, pp. 107-117
-
-
Kadaba, R.1
Birke, H.2
Wang, J.3
Hooper, S.4
Andl, C.D.5
Di Maggio, F.6
Soylu, E.7
Ghallab, M.8
Bor, D.9
Froeling, F.E.10
-
152
-
-
84964219080
-
Changing the course of pancreatic cancer—Focus on recent translational advances
-
Javle, M.; Golan, T.; Maitra, A. Changing the course of pancreatic cancer—Focus on recent translational advances. Cancer Treat. Rev. 2016, 44, 17–25.
-
(2016)
Cancer Treat. Rev
, vol.44
, pp. 17-25
-
-
Javle, M.1
Golan, T.2
Maitra, A.3
-
153
-
-
0030820092
-
Hyaluronan: Its nature, distribution, functions and turnover
-
Fraser, J.R.; Laurent, T.C.; Laurent, U.B. Hyaluronan: Its nature, distribution, functions and turnover. J. Intern. Med. 1997, 242, 27–33.
-
(1997)
J. Intern. Med
, vol.242
, pp. 27-33
-
-
Fraser, J.R.1
Laurent, T.C.2
Laurent, U.B.3
-
154
-
-
84858602107
-
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma
-
Provenzano, P.P.; Cuevas, C.; Chang, A.E.; Goel, V.K.; Hoff Von, D.D.; Hingorani, S.R. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21, 418–429.
-
(2012)
Cancer Cell
, vol.21
, pp. 418-429
-
-
Provenzano, P.P.1
Cuevas, C.2
Chang, A.E.3
Goel, V.K.4
Hoff Von, D.D.5
Hingorani, S.R.6
-
155
-
-
84975091164
-
Phase 1b Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer
-
Hingorani, S.R.; Harris, W.P.; Beck, J.T.; Berdov, B.A.; Wagner, S.A.; Pshevlotsky, E.M.; Tjulandin, S.; Gladkov, O.; Holcombe, R.F.; Korn, R.; et al. Phase 1b Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Clin. Cancer Res. 2016.
-
(2016)
Clin. Cancer Res
-
-
Hingorani, S.R.1
Harris, W.P.2
Beck, J.T.3
Berdov, B.A.4
Wagner, S.A.5
Pshevlotsky, E.M.6
Tjulandin, S.7
Gladkov, O.8
Holcombe, R.F.9
Korn, R.10
-
156
-
-
84954400636
-
Cancer statistics, 2016
-
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 2016, 66, 7–30.
-
(2016)
CA Cancer J. Clin
, vol.66
, pp. 7-30
-
-
Siegel, R.L.1
Miller, K.D.2
Jemal, A.3
-
157
-
-
84902147062
-
Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States
-
Rahib, L.; Smith, B.D.; Aizenberg, R.; Rosenzweig, A.B.; Fleshman, J.M.; Matrisian, L.M. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014, 74, 2913–2921.
-
Cancer Res
, vol.2014
, Issue.74
, pp. 2913-2921
-
-
Rahib, L.1
Smith, B.D.2
Aizenberg, R.3
Rosenzweig, A.B.4
Fleshman, J.M.5
Matrisian, L.M.6
|